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Sir,
According to Betts et al (2007), immune surveillance would be
limited by the inhibitory effect of naturally occurring forkhead box
P3 (FOXP3)-positive (þ) regulatory T cells. In mice, methylcho-
lanthrene-induced fibrosarcomas were strikingly infiltrated with
FOXP3þ regulatory T cells. The partial ablation of FOXP3þ
regulatory T-cell activity resulted in a marked reduction in tumour
incidence.
Increased frequencies of CD4þCD25
high T regulatory (Treg)
cells have been registered in the peripheral blood of patients with
several types of cancer, suggesting a putative role exerted by these
cells in tumour escape from immunological control. There is a
significant increased frequency of CD4þCD25
high T cells in
patients with renal cell carcinoma compared with normal donors
(Griffiths et al, 2007). These data were confirmed using the FOXP3
marker of Treg cells in a subset of these patients and normal
donors. The early follow-up data showed an association between
higher peripheral blood Treg cells count and adverse overall
survival (Griffiths et al, 2007). Similarly, an expansion of increase
of FOXP3þCD4þCD25
high Treg cells in peripheral blood and
tumour microenvironment has been demonstrated in nasophar-
yngeal carcinoma (NPC) patients (Lau et al, 2007). The expanded
Treg in the circulation also showed enhanced suppressive activity
on CD4þCD25  T-cell proliferations. The increase of this
functional Treg population would be able to reduce T-cell-
mediated antitumour immunity, since a significant decrease in
CD4þ T-cell populations in NPC patients was observed (Lau et al,
2007).
Ipilimumab, a fully human anticytotoxic T lymphocyte-
associated antigen-4 (CTLA-4) monoclonal antibody, depresses T
regulatory (Treg) cell numbers without increasing vaccine-specific
CD8þ T-cell responses in patients previously treated with
investigational anticancer vaccines (O’Mahony et al, 2007). Treg
cells, detected by expression of CD4þCD25þCD62Lþ, de-
creased at early time points after ipilimumab administration, with
a rebound increase by the time of the next treatment. Tumour
responses were limited to two patients with non-Hodgkin’s
lymphoma who experienced limited tumour regression at selected
metastatic sites. In one of these patient responders, reverse
transcription–polymerase chain reaction for FOXP3 mRNA
expression among peripheral blood mononuclear cells showed
that FOXP3 expression declined at early time points after
ipilimumab administration and rebounded to baseline values by
the time of the next infusion (O’Mahony et al, 2007).
CD4þCD25þFOXP3þ Treg cells are involved in the main-
tenance of suppressive control of aberrant immune responses.
Mutations in FOXP3 cause multi-organ autoimmunity in both
human and mouse (Marson et al, 2007). CD4þCD25þFOXP3þ
Tregs may impede the development of effective immunity to
autologous tumour cells (Yamaguchi and Sakaguchi, 2006), since
self-reactive T cells are continuously suppressed by Treg cells.
When suppression is relieved, self-reactive T cells become
activated and facilitate accelerated maturation of dendritic cells
(Kim et al, 2007). In fact, the immunisation of mice against FOXP3
elicits a robust FOXP3-specific CTL response, enhancing vaccine-
induced antitumour immunity (Nair et al, 2007). The combined
CD4þCD25þ regulatory T-cell inactivation and genetic vaccina-
tion resulted in significant tumour protection in a metastatic
tumour model (Elia et al, 2007). In another murine model, it has
been demonstrated that combining denileukin diftitox, a fusion pro-
tein of interleukin-2 and diphtheria toxin, with a vaccine enhances
antigen-specific T-cell immune responses (Litzinger et al, 2007).
Molecules upregulated on the surface of Treg cells, such as
CTLA-4 and CD25, are not expressed exclusively on Tregs
(Fontenot and Rudensky, 2004, 2005; Sakaguchi, 2004). The
effectiveness of targeting CD25 to eliminate Treg is limited by
the fact that CD25, the low-affinity interleukin-2 receptor, is
upregulated on conventional antigen-activated T cells (Fontenot
and Rudensky, 2004). The only gene product known to be
exclusively expressed in Tregs of mice is FOXP3 (Fontenot and
Rudensky, 2004). On the other hand, even though FOXP3
expression was initially thought to be restricted to the
CD4þCD25þ regulatory T-cell population, recent studies in
B-cell non-Hodgkin’s lymphoma showed that a subset of intra-
tumoural but not peripheral CD4þCD25  T cells express FOXP3
and are capable of suppressing the proliferation of autologous
infiltrating CD8þ T cells (Yang et al, 2007).
Nevertheless, based on the findings reported by Betts et al
(2007), FOXP3-positive Treg cells could represent an important
therapeutic target for cancer. The results of this study suggest a
role for Tregs in suppressing effective immune surveillance of
carcinogen-induced tumours in intact animals. Moreover, besides
the enhanced antitumour immunity, the FOXP3 vaccination could
lead to the preferential depletion of intratumoural but not
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(Nair et al, 2007). However, further studies are needed to better
clarify the weight of Treg depletion within the global immune
response to the tumour.
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